Skip to content

Optimization of vitreoretinal surgery for branch retinal vein occlusion combined with vitreous hemorrhage

Optimization of vitreoretinal surgery for branch retinal vein occlusion combined with vitreous hemorrhage

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017818
Enrollment
Unknown
Registered
2018-08-16
Start date
2018-11-14
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

branch retinal vein occlusion

Interventions

anti-VEGF group:vitreoretinal surgery combined with anti-VEGF
laser group:Vitreoretinal surgery combined with fan-shape photocoagulation

Sponsors

The Eye Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1) Aged >= 18 years; 2) Been diagnosed as BRVO; 3) Vitreous hemorrhage; 4) Vitreous hemorrhage combined with mild retinal fibrovascular proliferation (early fibrous vascular membrane, thin fibrous vascular membrane, loose retinal adhesion and intact local retinal structure).

Exclusion criteria

Exclusion criteria: 1) BRVO combined with severe retinal fibrovascular proliferation (long-term fibrovascular membrane, thick fibrous vascular membrane and tightly attached to the retina, deformation of local retinal, retinal tear or suspension of retinal vein); 2) BRVO combined with retinal detachment; 3) Retinalveins are completely whitened; 4) iris neovascularization or neovascular glaucoma; 5) Combined glaucoma; 6) combined with other retinopathy; 7) Received anti-VEGF treatment within 3 months before surgery.

Design outcomes

Primary

MeasureTime frame
best corrected visual acuity;visual field;

Secondary

MeasureTime frame
Macular retinal morphology;non-perfusion area of retinal ;vascular density of macular area;

Countries

China

Contacts

Public ContactYong Wei

The Eye Hospital of Wenzhou Medical University

weiyongdoctor@163.com+86 15057551266

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026